OncoCyte (OCX) Short Interest Ratio & Short Volume

Short interest is the volume of OncoCyte shares that have been sold short but have not yet been covered or closed out. As of May 15th, traders have sold 349,700 shares of OCX short. 3.05% of OncoCyte's shares are currently sold short. Learn More on OncoCyte's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. OCX shares currently have a short interest ratio of 6.0. Learn More on OncoCyte's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 3.05% of OncoCyte's floating shares are currently sold short.

OncoCyte saw a decline in short interest in May. As of May 15th, there was short interest totaling 349,700 shares, a decline of 6.5% from the previous total of 374,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

OncoCyte currently has issued a total of 8,270,000 shares. Some of OncoCyte's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. OncoCyte currently has a public float of 11,460,000 shares.

3.05% of OncoCyte's shares are currently sold short. Here is how the short interest of companies compare to OncoCyte: Cardio Diagnostics Holdings, Inc. (6.97%), Aspira Women's Health Inc. (2.18%), Trinity Biotech plc (0.10%), Biomerica, Inc. (2.04%), ImmuCell Co. (0.05%), Achilles Therapeutics plc (0.04%), DURECT Co. (3.13%), ARCA biopharma, Inc. (30.24%), Alpha Teknova, Inc. (0.34%), Iterum Therapeutics plc (7.70%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks.

Short selling OCX is an investing strategy that aims to generate trading profit from OncoCyte as its price is falling. OCX shares are trading down $0.14 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for OncoCyte occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of OCX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including OCX, twice per month. The most recent reporting period available is May, 15 2024.